Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis
文献类型：期刊论文
| 作者 | Song, Yuqin15; Gao, Quanli14; Zhang, Huilai13; Fan, Lei12; Zhou, Jianfeng11; Zou, Dehui9,10; Li, Wei8; Yang, Haiyan7; Liu, Ting6; Wang, Quanshun5 |
| 刊名 | CLINICAL CANCER RESEARCH
 |
| 出版日期 | 2022-03-15 |
| 卷号 | 28 |
| ISSN号 | 1078-0432 |
| DOI | 10.1158/1078-0432.CCR-21-2023 |
| 通讯作者 | Zhu, Jun(zhu-jun2017@outlook.com) |
| 英文摘要 | Purpose: Tislelizumab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody specifically designed to minimize binding to Fry receptors (Fc gamma R). Patients and Methods: Here, we present the extended 3-year follow-up of a phase II study of tislelizumab in 70 patients with relapsed/refractory classical Hodgkin lymphoma (cHL) who failed or were ineligible for autologous stem cell transplantation. Results: With a median follow-up of 33.8 months, the overall response rate by the independent review committee was 87.1%, and the complete response (CR) rate was 67.1%. Responses were durable as shown by a median duration of response of 31.3 months, and median progression-free survival (PPS) of 31.5 months. The 3-year PFS and overall survival rates were 40.8% and 84.8%, respectively. Treatment-related adverse events (TRAEs) of any grade occurred in 97.1% of patients; the grade >= 3 TRAE rate was low (31.4%), and only 8.6% of patients experienced adverse events leading to treatment discontinuation. Correlative biomarker analysis showed that Fc gamma RI-expressing macrophages had no observed impact on either the CR rate or PFS achieved with tislelizumab, which may be potentially related to its engineered Fc region. Conclusions: With extended follow-up, tislelizumab yielded long-term benefits and demonstrated a favorable safety profile for patients with relapsed/refractory cHL. |
| WOS关键词 | REED-STERNBERG CELLS ; B-CELL ; SINGLE-ARM ; BRENTUXIMAB VEDOTIN ; ANALYSIS REVEALS ; PHASE-II ; EXPRESSION ; TRANSPLANTATION ; MULTICOHORT ; MULTICENTER |
| 资助项目 | BeiGene (Beijing) Co., Ltd., Beijing, China ; BeiGene USA, Inc., San Mateo, CA ; Ify Sargeant, Kathryn Quinn ; Maxine Skipp on the behalf of Twist Medical |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| 出版者 | AMER ASSOC CANCER RESEARCH |
| WOS记录号 | WOS:000772209800001 |
| 资助机构 | BeiGene (Beijing) Co., Ltd., Beijing, China ; BeiGene USA, Inc., San Mateo, CA ; Ify Sargeant, Kathryn Quinn ; Maxine Skipp on the behalf of Twist Medical |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/128213]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Zhu, Jun |
| 作者单位 | 1.Bei Gene USA Inc, San Mateo, CA USA 2.Bei Gene Shanghai Co Ltd, Shanghai, Peoples R China 3.Bei Gene Beijing Co Ltd, Beijing, Peoples R China 4.Fudan Univ, Dept Med Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China 5.Chinese Peoples Liberat Army Gen Hosp, Dept Hematol, Beijing, Peoples R China 6.Sichuan Univ, West China Hosp, Dept Hematol, Chengdu, Peoples R China 7.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Lymphoma, Hangzhou, Peoples R China 8.Jilin Univ, Hosp 1, Dept Hematol, Canc Ctr, Changchun, Peoples R China 9.Chinese Acad Med Sci & Peking Union Med Coll, Coll Med, Blood Dis Hosp, Tianjin, Peoples R China 10.Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, Inst Hematol, Tianjin, Peoples R China |
| 推荐引用方式 GB/T 7714 | Song, Yuqin,Gao, Quanli,Zhang, Huilai,et al. Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis[J]. CLINICAL CANCER RESEARCH,2022,28. |
| APA | Song, Yuqin.,Gao, Quanli.,Zhang, Huilai.,Fan, Lei.,Zhou, Jianfeng.,...&Zhu, Jun.(2022).Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis.CLINICAL CANCER RESEARCH,28. |
| MLA | Song, Yuqin,et al."Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis".CLINICAL CANCER RESEARCH 28(2022). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。